Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung

Trial Profile

A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 04 Jun 2019 Results (n=96) resented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=27) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Feb 2018 Study protocol amended with addition of third treatment arm which includes apatinib dose as 375mg/d (SHR-1210 200mg,q2w plus apatinib 375mg/d).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top